Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuropace Inc (NQ: NPCE )

7.510 -0.050 (-0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neuropace Inc

NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
RNS System featured in over 50 Scientific Presentations and Posters 
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Participate in Upcoming Investor Conferences
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces CEO Transition
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales
To focus on commercial growth, including expanding adoption and driving higher utilization of NeuroPace’s RNS System 
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway
From NeuroPace, Inc.
Via Business Wire
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)
From NeuroPace, Inc.
Via Business Wire
NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents
From NeuroPace, Inc.
Via Business Wire
NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden
From NeuroPace
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.